Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine in Adolescents With Restless Legs Syndrome
NCT03992196Phase 3Terminated
- Sponsor
- UCB
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in restless legs syndrome (RLS), sponsored by UCB. Primary endpoints: Treatment-emergent Adverse Events at 14 months and Treatment-emergent Adverse Events Leading to Withdrawal at 14 months. Started Dec 2019; status: terminated.
02
Drugs
rotigotine
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT03992196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992196.